natgillin/translations-raw huggingface dataset:
The maintenance dose of voriconazole may be increased to 5 mg/kg intravenously BID or from 200 mg to 350 mg orally BID (100 mg to 200 mg
odmerek vorikonazola se lahko poveča na 5 mg/kg intravensko BID ali z 200 mg na 350 mg peroralno BID (s 100 mg na 200 mg peroralno
The maintenance dose seldom exceeds 0.5 mg per day.
Vzdrževalni odmerek je redko večji kot 0,5 mg na dan.
The maintenance dose will be then decided by your doctor to maintain the level of your haemoglobin within the target range.
Vzdrževalni odmerek bo zdravnik nato določil tako, da bo vašo koncentracijo hemoglobina vzdrževal v ciljnem območju.
The maintenance dose: Once your red blood cells reach an acceptable level, the dose is reduced to half of the dose used to correct the anaemia.
Vzdrževalni odmerek: ko bo vaša koncentracija rdečih krvnih celic zadostna, bo odmerek zmanjšan na polovico odmerka, ki je bil potreben za popravljanje anemije.
The maintenance studies showed that long-term treatment with Rapamune was effective in helping the new kidney to survive, with an improvement in how well the new kidney worked and an improvement in blood pressure when ciclosporin treatment was stopped.
Vzdrževalne študije so pokazale, da je dolgoročno zdravljenje z zdravilom Rapamune učinkovito in da pripomore k preživetju in boljšemu delovanju nove ledvice ter izboljša krvni tlak po prenehanju jemanja ciklosporina.
The maintenance study (IM-UNITI), evaluated 388 patients who achieved 100 point clinical response at week 8 of induction with ustekinumab in studies UNITI-1 and UNITI-2.
V 1. študiji psoriaze so v 2. in 12. tednu dokazali bistveno izboljšanje DLQI glede na začetek študije v vseh terapevtskih skupinah z ustekinumabom v primerjavi s placebom.
The major circulating entity was raltegravir and represented approximately 70 % of the total radioactivity; the remaining radioactivity in plasma was accounted for by raltegravir-glucuronide.
Glavna snov v obtoku je bil raltegravir, na katerega je odpadlo približno 70 % skupne radiokativnosti, preostala radioaktivnost v plazmi je bila posledica raltegravirjevega glukuronida.
The major circulating metabolite is the 10-N-glucuronide, which does not pass the blood brain barrier.
V krvi je poglavitni metabolit 10- N-glukuronid, ki ne prehaja skozi krvno-možgansko pregrado.
The major circulating metabolite is the 10-N-glucuronide, which does not pass the blood brain barrier.
V krvi je poglavitni metabolit 10-N- glukuronid, ki ne prehaja skozi krvno-možgansko pregrado.
The major circulating metabolite is the 10-N-glucuronide, which does not pass the blood brain barrier.
V krvi je poglavitni metabolit 10-N- glukuronid, ki ne prehaja skozi krvno-možganskopregrado.
The major compounds excreted in urine are unchanged lacosamide (approximately 40% of the dose) and its O-desmethyl metabolite less than 30%.
Glavni spojini, ki se izločata s sečem, sta nespremenjeni lakozamid (približno 40 % odmerka) in njegov O-desmetilni presnovek (manj kot 30 %).
The major degradation product of pravastatin is the 3-α- hydroxy isomeric metabolite.
Glavni produkt razgradnje pravastatina je izomerni metabolit 3-α-hidroksi.
The major dose limiting toxicities of lenalidomide include neutropenia and thrombocytopenia.
Nevtropenija in trombocitopenija sta med glavnimi toksičnimi učinki, ki omejujejo odmerjanje lenalidomida.
The major exclusion criteria for patients were documented peptic ulcer disease within the previous
Glavna merila za nevključitev bolnikov so bila potrjena peptična ulkusna bolezen v preteklih 6 mesecih, predhodna intracerebralna krvavitev, pomembna trombocitopenija (število trombocitov
The major excretion route is via urine, accounting for about 50% of the dose.
Glavna pot izločanja je z urinom, ki predstavlja približno 50 % odmerka.
The major identified metabolic pathways are oxidation and degradation of the imidazole and piperazine rings, oxidative O-dealkylation and aromatic hydroxylation.
Glavne ugotovljene presnovne poti so oksidacija in razpad imidazolnih ter piperazinskih obročev, oksidativna O-dealkilacija in aromatska hidroksilacija.
The major metabolite (a para-hydroxy-sulphate) with high affinity to the soluble human PPAR, exhibited relatively high potency in a glucose tolerance assay in obese mice.
Glavni metabolit (parahidroksisulfat) z močno afiniteto do topnega humanega PPARγ je v raziskavi, ki je preučevala toleranco za glukozo pri debelih miših, izkazal sorazmerno visoko učinkovitost.
The major metabolite (a para-hydroxy-sulphate) with high affinity to the soluble human PPAR, exhibited relatively high potency in a glucose tolerance assay in obese mice.
Glavni presnovek (parahidroksisulfat), ki ima veliko afiniteto za topni humani PPARγ, je v preizkusu tolerance za glukozo pri debelih miših pokazal razmeroma veliko moč.
The major metabolite (para-hydroxy-sulphate) with high affinity to the soluble human PPAR, exhibited relatively high potency in a glucose tolerance assay in obese mouse.
Glavni presnovek (parahidroksisulfat) z visoko afiniteto do topnega človeškega PPARγ je v raziskavi, ki je preučevala toleranco za glukozo pri debelih miših, izkazal sorazmerno visoko učinkovitost.
The major metabolite identified was O-desmethyl gefitinib, which is
Glavni identificirani presnovek je O-dezmetilgefitinib.
The major metabolite in plasma is formed by O- dealkylation, referred to as metabolite M-II, and the minor metabolite is formed by decarboxylation, referred to as metabolite M-I.
Glavni presnovek v plazmi, presnovek M-II, nastane z O-dealkilacijo, stranski presnovek M-I nastane z dekarboksilacijo.
The major metabolite NAP226- 90 also did not show a genotoxic potential.
Tudi najpomembnejši presnovek NAP226-90 ni kazal genotoksičnega potenciala
The major metabolite NAP226- 90 also did not show a genotoxic potential.
Tudi najpomembnejši presnovek NAP226-90 ni kazal genotoksičnega potenciala.
The major metabolite of saxagliptin is also a selective, reversible, competitive DPP4 inhibitor, half as potent as saxagliptin.
Tudi glavni presnovek saksagliptina je selektiven, reverzibilen, kompetitiven zaviralec DPP-4, pol tako močan kot saksagliptin.
The major metabolite of tylvalosin is 3-acetyltylosin (3-AT), which is also microbiologically active.
Glavni presnovek tilvalozina je 3-acetil-tilozin (3AT), ki je tudi mikrobiološko delujoč.
The major metabolite of tylvalosin is 3-acetyltylosin (3-AT), which is also microbiologically active.
Glavni presnovek tilvalozina je 3-acetil-tilozin (3AT), ki tudi deluje na mikrobe.
The major metabolite of tylvalosin is 3-acetyltylosin (3-AT), which is also microbiologically active.
Poglavitni presnovek tilvalozina je 3-acetiltilozin (3-AT), ki tudi protimikrobno deluje.
The major metabolite, demethylated cimicoxib is mainly eliminated in faeces by the biliary route and, to a lesser extent, in urine.
Glavni metabolit, demetiliran cimikoksib se večinoma izloča z žolčem preko blata, v manjši količini z urinom.
The major metabolites found in all species were the 5-hydroxy- and 5-carboxy- metabolites and the oxalyl- metabolite.
Poglavitni presnovki, ki so jih odkrili pri vseh vrstah, so 5-hidroksi- in 5- karboksi- presnovki ter oksalil-presnovek.
The major metabolites found in all species were the 5-hydroxy- and 5-carboxy- metabolites and the oxalyl- metabolite.
Poglavitni presnovki, ki so jih odkrili pri vseh vrstah, so 5-hidroksi- in 5- karboksi-presnovki ter oksalil-presnovek.
The major metabolites found in all species were the 5-hydroxy- and 5-carboxy- metabolites and the oxalyl-metabolite.
Poglavitni presnovki, ki so jih odkrili pri vseh vrstah, so 5-hidroksi- in 5- karboksi-presnovki ter oksalil-presnovek.
The major metabolites found in all species were the 5-hydroxy- and 5-carboxy-metabolites and the oxalyl-metabolite.
Glavni presnovki, ki so jih odkrili pri vseh vrstah so 5-hidroksi- in 5-karboksi- presnovki ter oksalil-presnovek.
The major metabolites found in all species were the 5-hydroxy- and 5-carboxy-metabolites and the oxalyl-metabolite.
Poglavitni presnovki, ki so jih odkrili pri vseh vrstah, so 5-hidroksi- in 5- karboksi-presnovki ter oksalil-presnovek.
The major metabolites of PAS are produced by conjugation to glycine in para-aminosalicyluric acid (PASU) for up to 25% of the dose and to N-acetyl in N-acetyl para-aminosalicylic acid (Ac-PAS) for up to 70% of the dose.
Glavna presnovka para-aminosalicilne kisline nastaneta s konjugacijo: z glicinom v para- aminosalicilurno kislino (PASU) (do 25 % odmerka) in z N-acetilom v N-acetil-para-aminosalicilno kislino (Ac-PAS) (do 70 % odmerka).
The major oxidative metabolite, M8 (tert- butyl hydroxy nelfinavir), has in vitro antiviral activity equal to the parent drug and its formation is catalysed by the polymorphic cytochrome CYP2C19.
Glavni oksidirani presnovek, M8 (terc-butil hidroksinelfinavir), ima in vitro enako protivirusno aktivnost kot učinkovina, njegovo tvorbo katalizira polimorfni citokrom CYP2C19.
The major part is hydrogenated or hydroxylated in humans, the major metabolites being hydroxy-6-dexamethasone and dihydro-20-dexamethasone.
Večji del se pri ljudeh hidrogenira ali hidroksilira, pri čemer sta glavna presnovka hidroksi-6-deksametazon in dihidro-20- deksametazon.
The major route of 14C elimination is renal.
Glavna pot izločanja 14C-označenega TMZ je preko ledvic.
The major route of 14C elimination is renal.
Glavna pot izločanja 14C-označenega TMZ je preko ledvice.
The major route of biotransformation of clomipramine is demethylation to desmethylclomipramine.
Največ klomipramina se z desmetilacijo metabolizira v desmetilklomipramin.
The major route of elimination of drug related radioactivity after oral administration of [14C] nintedanib was via faecal/biliary excretion (93.4 % of dose, 2.61 % gCV).
Glavna pot izločanja z zdravilom povezane radioaktivnosti po zaužitju [14C] nintedaniba je bila izločanje z blatom/žolčem (93,4 % odmerka, 2,61 % gCV).
The major route of elimination of drug related radioactivity after oral administration of [14C] nintedanib was via faecal/biliary excretion (93.4% of dose,
Glavna pot izločanja z zdravilom povezane radioaktivnosti po zaužitju [14C] nintedaniba je bila izločanje z blatom/žolčem (93,4 % odmerka, 2,61 % gCV).
The major route of excretion is in faeces for indoxacarb and both in urine and faeces for permethrin.
V glavnem se metaboliti indoksakarba izločajo z blatom, metaboliti peremetrina pa z urinom in s fecesom.
The major route of excretion of radiolabeled bazedoxifene is the faeces, and less than 1% of the dose is eliminated in urine.
Glavna pot izločanja radioaktivno označenega bazedoksifena je blato, manj kot 1 % odmerka pa se izloči z urinom.
The major route of excretion was via the urine (>90%) while faecal excretion was minor.
Večina odmerka se je izločila z urinom (>90 %), izločanje s fecesom pa je bilo manj pomembno.
The major target organs were the lymphoid system (lymphopenia and lymphoid atrophy), lungs (increased weight, smooth muscle hypertrophy at the bronchio-alveolar junction), and heart (negative chronotropic effect, increase in blood pressure, perivascular changes and myocardial degeneration) in several species; blood vessels (vasculopathy) in rats only at doses of 0.15 mg/kg and higher in a 2- year study, representing an approximate 4-fold margin based on the human systemic exposure (AUC) at a daily dose of 0.5 mg.
V 2-letni študiji so bili pri odmerkih 0,15 mg/kg in več, kar predstavlja približno 4-kratnik sistemske izpostavljenosti (AUC) pri ljudeh pri odmerjanju 0,5 mg na dan najbolj pomembni tarčni organi pri več vrstah živali limfatični sistem (limfopenija in atrofija limfatičnega tkiva), pljuča (povečanje mase, hipertrofija gladkih mišic na stiku med bronhioli in alveoli) in srce (negativen kronotropni učinek, zvišanje krvnega tlaka, perivaskularne spremembe in degeneracija srčne mišice); samo pri podganah pa krvne žile (vaskulopatija).
The majority (70.4%) of patients had Stable Disease as a best response (based on Investigator’s assessment using RECIST criteria) and 29.6% patients had Progressive Disease as their best overall response.
Pri večini (70,4 %) bolnikov je bil najboljši odziv stabilna bolezen (glede na oceno raziskovalca z merili RECIST), pri 29,6 % bolnikov pa je bil najboljši skupni odziv napredujoča bolezen.
The majority (95%) of IRRs occurred at the first infusion.
Do večine (95%) infuzijskih reakcij je prišlo pri prvi infuziji.
The majority of ADRs reported were of Grade 1 or 2 severity. the most common National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade ≥ 3 ADRs (> 2%) were thrombocytopenia, increased transaminases, anaemia, neutropenia, fatigue, hypokalaemia, musculoskeletal pain and haemorrhage.
Večina opisanih neželenih učinkov je bila 1. ali 2. stopnje. najpogostejši neželeni učinki ≥ 3. stopnje po NCI-CTCAE (National Cancer Institute – Common Terminology Criteria for Adverse Events), (> 2 %): trombocitopenija, zvišanje transaminaz, anemija, nevtropenija, utrujenost, hipokaliemija, mišično-skeletne bolečine in krvavitev.
The majority of adverse drug reactions were mild to moderate, they usually start early in therapy and most tended to disappear even as therapy was continued.
Neželeni učinki so bili večinoma blagi do zmerni, običajno so se pojavili v zgodnjem obdobju zdravljenja, pri večini pa je kazalo, da bodo med nadaljevanjem zdravljenja minili.
The majority of adverse drug reactions were mild to moderate, they usually start early in therapy and most tended to disappear even as therapy was continued.
Neželeni učinki so bili večinoma blagi do zmerni, običajno so se pojavljali v zgodnjem obdobju zdravljenja in večina jih je izginila, četudi so bolniki zdravljenje nadaljevali.
The majority of adverse reactions are mild and transient.
Večina neželenih učinkov je blagih in prehodnih.
The majority of adverse reactions experienced by patients treated with eptifibatide were generally related to bleeding or to cardiovascular events that occur frequently in this patient population.
Večina neželenih učinkov, ki so jih imeli bolniki, zdravljeni z eptifibatidom, je bila praviloma povezana s krvavitvami ali kardiovaskularnimi pojavi, ki so v tej populaciji bolnikov tudi sicer pogosti.
The majority of adverse reactions presented in Table 3 were of grade 1 severity in Exviera- and ombitasvir/paritaprevir/ritonavir-containing regimens.
Večina neželenih učinkov, predstavljenih v preglednici 3, je bila v shemah z zdravilom Exviera in kombinacijo ombitasvir/paritaprevir/ritonavir 1. stopnje glede na resnost.
The majority of adverse reactions presented in Table 3 were of grade 1 severity in Viekirax and dasabuvir- containing regimens.
Večina neželenih učinkov, predstavljenih v preglednici 3, je bila v shemah, ki so vključevale zdravilo Viekirax in dasabuvir, 1. stopnje glede na resnost.
The majority of adverse reactions reported were of Grade 1 or 2 severity.
Večina poročanih neželenih učinkov je bila po izrazitosti 1. ali 2. stopnje.
The majority of adverse reactions reported with GANFORT single-dose were ocular, mild in severity and none were serious.
Večina neželenih učinkov, o katerih so poročali pri uporabi zdravila GANFORT (enoodmerna oblika), je bila lokalnih in blagih.
The majority of bleeding events were mild.
Večina krvavitev je bilo blagih.
The majority of cases had an outcome of recovered or resolved following dose interruption or reduction, which occurred in 16.9% and 10.7% of patients, respectively.
Pri večini primerov je bil izid ozdravitev ali okrevanje po prekinitvi ali zmanjšanju odmerka, kar se je zgodilo pri 16,9 % oziroma 10,7 % bolnikov.
The majority of cases recovered or resolved following dose interruption or reduction, which occurred in 13.0% and 13.4% of patients, respectively.
Večina primerov je ozdravila ali okrevala po prekinitvi ali zmanjšanju odmerjanja, kar se je zgodilo pri 13,0 % oziroma 13,4 % bolnikov.
The majority of cases were associated with additional adverse drug reactions such as erythema, flushing, skin burning sensation, condition aggravated and rash.
Večina primerov je bila povezana z dodatnimi neželenimi učinki, kot so eritem, pordelost, občutek pekoče kože, poslabšanje stanja in izpuščaj.
The majority of DepoCyte patients went on beyond Induction to receive additional therapy.
Večina bolnikov, ki so prejemali zdravilo DepoCyte, je po začetni fazi zdravljenja dobila dodatno zdravljenje.
The majority of enzyme elevations were <3 times the upper limit of normal (ULN).
Večina povečanja encima je bila < 3-kratna zgornja meja normalne vrednosti (ULN, upper limit of normal).
The majority of events resolved after treatment interruption.
Večina učinkov je minila po prekinitvi zdravljenja.
The majority of events were Grade 1 or 2 and non-serious (12% of patients in the Cotellic plus vemurafenib arm vs 7% patients in the placebo plus vemurafenib arm).
Večina dogodkov je bila stopnje 1 ali 2 in niso bili resni (12 % bolnikov v skupini z zdravilom Cotellic in vemurafenibom, 7 % pri bolnikih v skupini s placebom in vemurafenibom).
The majority of events were Grades 1 or 2, with
Večina dogodkov je bila stopnje 1 ali 2.
The majority of headaches reported with CIALIS once-a- day dosing are experienced within the first 10 to 30 days of starting treatment.
Večino glavobolov, o katerih poročajo bolniki, ki jemljejo zdravilo CIALIS v odmerku enkrat na dan, bolniki občutijo v prvih 10 do 30 dneh po začetku zdravljenja.
The majority of headaches reported with tadalafil once-a-day dosing are experienced within the first 10 to 30 days of starting treatment.
Večino glavobolov, o katerih poročajo bolniki, ki jemljejo tadalafil v odmerku enkrat na dan, bolniki občutijo v prvih 10 do 30 dneh po začetku zdravljenja.
The majority of imatinib-intolerant patients with chronic phase CML were able to tolerate treatment with SPRYCEL.
Zdravljenje z zdravilom SPRYCEL je prenašala večina na imatinib odpornih bolnikov s KML v kroničnem obdobju.
The majority of infusion reactions were Grade 1 or Grade 2 in severity.
Po intenzivnosti je bila večina infuzijskih reakcij 1. ali 2. stopnje.
The majority of lamivudine is excreted unchanged in the urine via glomerular filtration and active secretion (organic cationic transport system).
Lamivudin se večinoma izloča v urin nespremenjen preko glomerularne filtracije in aktivne sekrecije (organski kationski transportni sistem).
The majority of lamivudine is excreted unchanged in the urine via glomerular filtration and active secretion (organic cationic transport system).
Lamivudin se večinoma nespremenjen izloča v urin z glomerularno filtracijo in aktivno sekrecijo (organski kationski transportni sistem).
The majority of methicillin-resistant S. aureus (MRSA) express cMLSB.
Večina proti meticilinu odpornih S. aureus (MRSA) ima eksprimirano cMLSB.
The majority of patients (58%) had LDL- cholesterol > 190 mg/dl at study entry, and 24% of patients with LDL-cholesterol > 190 mg/dl were on lipid lowering medicinal products.
Večina bolnikov (58%) je imela ob vstopu v študijo holesterol LDL > 190 mg/dl in 24% bolnikov, ki je imelo holesterol LDL > 190 ml/dl je jemalo zdravila za zmanjševanje maščob.
The majority of patients (81%) showed signs of B cell return, with counts >10 cells/μL by month 12, increasing to 87% of patients by month 18.
Pri večini bolnikov (81 %) se je število celic B ponovno povečalo na > 10 celic/µl do 12. meseca, do 18. meseca pa še pri večjem, 87-% deležu bolnikov.
The majority of patients (83%) had visceral metastases at baseline.
Večina bolnikov (83 %) je imela visceralne metastaze ob izhodišču.
The majority of patients achieved an optimised dose between 0.05-0.12mg/kg/day.
Večina bolnikov je dosegla optimiziran odmerek med 0,05 in
The majority of patients do not require termination of TRISENOX therapy during treatment of the APL differentiation syndrome.
Pri večini bolnikov med zdravljenjem sindroma diferenciacije APL ni potrebna prekinitev zdravljenja z zdravilom TRISENOX.
The majority of patients experience chills (89%), fever (85%) and fatigue (53%).
Pri večini bolnikov se je pojavila mrzlica (89 %), zvišana telesna temperatura (85 %) in utrujenost (53 %).
The majority of patients experienced maintenance and/or improvement in their disease-related symptoms, functioning, and health status.
Pri večini bolnikov je prišlo do ohranjanja stanja oziroma do izboljšanja z boleznijo povezanih simptomov, funkcioniranja in zdravstvenega stanja.
The majority of patients had a long history of CML that included extensive prior treatment with other antineoplastic agents, including imatinib, hydroxyurea, interferon, and some had even failed organ transplant (Table 9).
Večina bolnikov je imela KML že dolgo in so bili predhodno v veliki meri zdravljeni z drugimi antineoplastičnimi zdravili, vključno z imatinibom, s hidroksiureo, z interferonom, pri nekaterih celo transplantacija kostnega mozga ni bila uspešna (preglednica 9).
The majority of patients had either favourable (39 %) or intermediate (54 %), MSKCC (Memorial Sloan Kettering Cancer Centre) / Motzer prognostic factors.
Večina bolnikov je imela bodisi ugoden (39 %) bodisi vmesen (54 %) MSKCC (Memorial Sloan Kettering Cancer Centre) ali Motzer-jev prognostični faktor.
The majority of patients had received MabThera in combination with chemotherapy or as part of a haematopoetic stem cell transplant.
Večina bolnikov je prejemala zdravilo MabThera v kombinaciji s kemoterapijo ali v okviru presaditve krvotvornih matičnih celic.
The majority of patients had received MabThera in combination with chemotherapy or as part of a hematopoietic stem cell transplant.
Večina bolnikov je prejela zdravilo MabThera v kombinaciji s kemoterapijo ali v okviru presaditve krvotvornih matičnih celic.
The majority of patients in the phase 3 program were taking background lipid-modifying therapy consisting of a maximally tolerated dose of statin, with or without other lipid- modifying therapies, and were at high or very high cardiovascular (CV) risk.
Večina bolnikov v programu 3. faze je jemala osnovno zdravljenje za prilagoditev lipidov, ki je obsegalo največji tolerirani odmerek statina z drugimi zdravili za prilagoditev lipidov ali brez njih, in so imeli veliko ali zelo veliko kardiovaskularno (KV) tveganje.
The majority of patients in these studies were using immunomodulatory medicines.
Večina bolnikov v tej študiji je uporabljala imunomodulatorje.
The majority of patients included in studies with Kyprolis received antiviral prophylaxis; due to this fact it is not possible to calculate the true incidence of herpes zoster infection in patients treated with Kyprolis.
V študijah zdravila Kyprolis je večina bolnikov dobivala protivirusno profilakso, zato dejanske incidence herpesa zostra pri bolnikih, zdravljenih s zdravilom Kyprolis, ni mogoče izračunati.
The majority of patients treated with Xultophy in these studies achieved control of their blood glucose (HbA1c below 7.0%) and many achieved HbA1c below 6.5%.
Pri večini bolnikov, ki so se v navedenih študijah zdravili z zdravilom Xultophy, se je uravnavanje glukoze v krvi izboljšalo (HbA1c nižji od 7.0%), pri mnogih pa je bila dosežena raven nižja od 6,5 %.
The majority of patients were also receiving one or more of the following concomitant treatments for SLE: corticosteroids, immunomodulatory medicinal products, anti-malarials, non-steroidal anti-inflammatory medicinal products.
Večina bolnikov je za SLE sočasno dobivala tudi eno ali več naslednjih zdravil: kortikosteroide, imunomodulacijska zdravila, antimalarike, nesteroidna protivnetna zdravila.
The majority of patients were diagnosed with idiopathic or heritable pulmonary arterial hypertension (61%).
Večina bolnikov je bila diagnosticirana z idiopatsko ali podedovano pljučno arterijsko hipertenzijo (61 %).
The majority of patients were non-Asian (81.6 %), the median age was 60.0 years, the baseline ECOG performance status was 0 (28.6 %) or 1 (71.3 %); one patient had a baseline ECOG performance status of 2.
Večina bolnikov je bilo Neazijcev (81,6 %), mediana starost je bila 60,0 let, izhodiščno stanje zmogljivosti po ECOG je bilo 0 (28,6 %) ali 1 (71,3 %); en bolnik je imel izhodiščno stanje zmogljivosti po ECOG 2.